Daratumumab, a fully humanized IgGκ anti‐CD38 monoclonal antibody, exerts its anti‐MM activity through numerous mechanisms, such as antibody‐dependent cellular cytotoxicity, antibody‐dependent cellular phagocytosis, direct cellular apoptosis, and modulation of extracellular ectoenzyme activity.4 This evidence concerns the gene CD38 and Miyoshi myopathy.